Neurocrine Biosciences Reports Third Quarter 2026 Financial Results

Neurocrine Biosciences reported third-quarter 2026 revenue of $1.12 billion, up 41% year over year, with product sales of $801 million for INGREZZA, $211 million for CRENESSITY and $107 million for VYKAT XR. Adjusted earnings were $346.7 million, or $3.29 per share, and quarterly net product sales exceeded $1 billion. The company raised its 2026 INGREZZA net sales guidance to $2.9 billion–$2.925 billion. It also cited upcoming Phase 3 readouts for osavampator and direclidine; the article did not report a stock-price reaction.